Surmodics, Inc. (SRDX): Price and Financial Metrics


Surmodics, Inc. (SRDX)

Today's Latest Price: $38.12 USD

0.91 (2.45%)

Updated Nov 23 4:00pm

Add SRDX to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 58 in Medical - Diagnostics/Research

See all "A" rated Strong Buy stocks

SRDX Stock Summary

  • SRDX's current price/earnings ratio is 66.63, which is higher than 86.94% of US stocks with positive earnings.
  • For SRDX, its debt to operating expenses ratio is greater than that reported by only 0.52% of US equities we're observing.
  • In terms of twelve month growth in earnings before interest and taxes, Surmodics Inc is reporting a growth rate of 220.49%; that's higher than 93.59% of US stocks.
  • If you're looking for stocks that are quantitatively similar to Surmodics Inc, a group of peers worth examining would be INS, SILC, TNAV, SIMO, and KLIC.
  • Visit SRDX's SEC page to see the company's official filings. To visit the company's web site, go to www.surmodics.com.

SRDX Stock Price Chart Interactive Chart >

Price chart for SRDX

SRDX Price/Volume Stats

Current price $38.12 52-week high $49.00
Prev. close $37.21 52-week low $22.06
Day low $36.98 Volume 41,864
Day high $38.32 Avg. volume 66,916
50-day MA $39.07 Dividend yield N/A
200-day MA $39.15 Market Cap 518.66M

Surmodics, Inc. (SRDX) Company Bio


SurModics Inc. provides surface modification and in vitro diagnostic technologies to the healthcare industry. The company operates through two segments, Medical Device and In Vitro Diagnostics. The company was founded in 1979 and is based in Eden Prairie, Minnesota.

SRDX Price Forecast Based on DCF Valuation

Current PriceDCF Fair Value Target: Forecasted Gain:
$38.12$13.58 -63%

We started the process of determining a valid price forecast for Surmodics Inc with a discounted cash flow analysis -- the results of which can be found in the table below. To summarize, we found that Surmodics Inc ranked in the 25th percentile in terms of potential gain offered. We should note, though, that the most conservative analysis suggests this stock will yield negative results -- and thus may be a potential short opportunity. In terms of the factors that were most noteworthy in this DCF analysis for SRDX, they are:

  • The business' balance sheet reveals debt to be 0% of the company's capital (with equity being the remaining amount). Approximately merely 0.05% of US stocks with free cash flow have a lower reliance on debt in their capital structure.
  • The company's cost of debt, derived from its interest coverage, tax rate, and market capitalization, is greater than only 0% of stocks in its sector (Healthcare).


Terminal Growth Rate in Free Cash FlowReturn Relative to Current Share Price
0%-64%
1%-64%
2%-63%
3%-63%
4%-63%
5%-62%

A, BIO, ILMN, VIVO, and XRAY can be thought of as valuation peers to SRDX, in the sense that they are in the Healthcare sector and have a similar price forecast based on DCF valuation.


SRDX Latest News Stream


Event/Time News Detail
Loading, please wait...

SRDX Latest Social Stream


Loading social stream, please wait...

View Full SRDX Social Stream

Latest SRDX News From Around the Web

Below are the latest news stories about Surmodics Inc that investors may wish to consider to help them evaluate SRDX as an investment opportunity.

FDA clears Surmodics Pounce Thrombus Retrieval System

Surmodics (SRDX) has received FDA 510(k) clearance for its Pounce Thrombus Retrieval System for the treatment of peripheral artery disease ((PAD)). The Pounce Thrombus is intended for the non-surgical removal of thrombi and emboli from the peripheral arterial vasculature. PAD is a serious and underdiagnosed circulatory condition caused by build-up of...

Seeking Alpha | September 23, 2020

Surmodics, Inc. (SRDX) CEO Gary Maharaj on Q3 2020 Results - Earnings Call Transcript

Surmodics, Inc. (SRDX) Q3 2020 Earnings Conference Call August 5, 2020 17:00 ET Company Participants Tim Arens - Vice President, Finance & Chief Financial Officer Gary Maharaj - Chief Executive Officer Conference Call Participants Jim Sidoti - Sidoti & Company Brooks O'Neil - Lake Street Capital Markets David Saxon -...

SA Transcripts on Seeking Alpha | August 10, 2020

Surmodics Reports Third Quarter Fiscal 2020 Results

EDEN PRAIRIE, Minn.--(BUSINESS WIRE)-- #Surmodics--Surmodics Reports Third Quarter Fiscal 2020 Results and will hold a webcast conference call at 4 pm CT.

Business Wire | August 5, 2020

Analysts Estimate SurModics (SRDX) to Report a Decline in Earnings: What to Look Out for

SurModics (SRDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Yahoo | July 29, 2020

Surmodics to Webcast Third Quarter Fiscal 2020 Earnings Conference Call on August 5

EDEN PRAIRIE, Minn.--(BUSINESS WIRE)-- #Surmodics--Surmodics issues an earnings release after market closes and will host a webcast of fiscal 2020 third-quarter conference call on August 5 at 4 pm CT.

Business Wire | July 28, 2020

Read More 'SRDX' Stories Here

SRDX Price Returns

1-mo -6.84%
3-mo -17.74%
6-mo -2.58%
1-year -5.24%
3-year 17.11%
5-year 75.10%
YTD -7.99%
2019 -12.34%
2018 68.79%
2017 10.24%
2016 25.31%
2015 -8.28%

Continue Researching SRDX

Here are a few links from around the web to help you further your research on Surmodics Inc's stock as an investment opportunity:

Surmodics Inc (SRDX) Stock Price | Nasdaq
Surmodics Inc (SRDX) Stock Quote, History and News - Yahoo Finance
Surmodics Inc (SRDX) Stock Price and Basic Information | MarketWatch


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.8583 seconds.